Education
About Us
Working with TipRanks
Follow Us
Cellebrite Di Ltd. (CLBT)
:CLBT
Top Page
Cellebrite DI
(NASDAQ:CLBT)
63Neutral
Positive Factors
AI and product competitiveness
AI and generative AI features help improve the competitiveness of Cellebrite's products.
Financial performance
The company offers a compelling investment opportunity as a market leader, growing ARR over 20%, with a strong cash position and no debt.
Market opportunities
Partnership with Relativity helps drive potential enterprise market opportunities.
Negative Factors
Leadership stability
The company is actively searching for its next permanent CEO, which adds uncertainty to leadership stability.
Political impact
Modest Political Headwinds – Cellebrite gave a healthy guide for Q1'25, but it would have been higher had the business not been impacted by regime change in certain countries.
Stock performance
Shares are likely down on profit-taking, some U.S. federal deals getting pushed to the right, and the 2025 margin guidance that implies modest contraction.
Cellebrite DI (CLBT) vs. S&P 500 (SPY)
Market Cap
$4.82B
Dividend YieldN/A
Average Volume (3M)976.58K
Price to Earnings (P/E)―
Beta (1Y)1.23
Revenue Growth23.41%
EPS Growth-222.82%
CountryUS
Employees1,167
SectorTechnology
Sector Strength67
IndustrySoftware - Infrastructure
Share Statistics
EPS (TTM)0.08
Shares Outstanding239,470,060
10 Day Avg. Volume752,635
30 Day Avg. Volume976,582
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit14.80
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$27.20Price Target Upside35.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Cellebrite DI Business Overview & Revenue Model
Company DescriptionCellebrite DI (CLBT) is a leading provider of digital intelligence solutions, catering primarily to the law enforcement, government, and enterprise sectors. The company specializes in providing tools and services designed to accelerate investigations and enhance decision-making processes through the extraction, analysis, and management of digital data from various devices. With a focus on digital forensics, Cellebrite's core products include advanced software and hardware solutions for data collection, analysis, and reporting.
How the Company Makes MoneyCellebrite makes money through the sale of its proprietary digital intelligence software and hardware solutions. The company's revenue model is primarily based on licensing fees for its software products, which include data extraction tools and analytics platforms, as well as sales of hardware solutions designed for digital data collection. Additionally, Cellebrite offers subscription-based services for ongoing support, updates, and training, providing a steady stream of recurring revenue. Key revenue streams include contracts with law enforcement agencies, government entities, and private enterprises that require sophisticated digital forensics capabilities. Significant partnerships with technology firms and law enforcement organizations also contribute to its earnings by expanding its product reach and enhancing its service offerings.
Cellebrite DI Financial Statement Overview
Summary
Cellebrite DI demonstrates strong revenue growth and operational improvements. However, it faces challenges with profitability due to negative net income and historical negative equity. Despite these challenges, the company has robust cash flow generation, indicating operational stability.Income Statement
Cellebrite DI has shown consistent revenue growth with a significant increase from 2023 to 2024. The gross profit margin is strong, though the net profit margin is negative due to high expenses leading to net losses. The EBIT margin shows improvement, indicating operational efficiency in recent years. However, the EBITDA margin is negative, reflecting substantial non-operating expenses or adjustments.65
Positive
Balance Sheet
The company's debt-to-equity ratio is low, suggesting minimal reliance on debt financing. However, the negative stockholders' equity in 2021 could indicate financial instability during that period. The return on equity is not calculable due to negative equity in some years, and the equity ratio shows fluctuations, reflecting changes in the company's asset base and equity.55
Neutral
Cash Flow
Cellebrite DI exhibits strong cash flow generation with positive operating and free cash flows, which have grown over time. The free cash flow to net income ratio is not favorable due to the net losses. However, the operating cash flow to net income ratio suggests that the company is generating sufficient cash from operations despite the net losses, indicating good cash flow management.70
Positive
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 401.20M | 325.11M | 270.65M | 246.25M | 194.91M | Gross Profit |
| 338.61M | 271.88M | 219.91M | 203.69M | 157.03M | EBIT |
| 56.91M | 33.24M | 1.04M | 13.82M | 9.22M | EBITDA |
| -265.38M | -64.80M | 10.24M | 89.88M | 16.95M | Net Income Common Stockholders |
| -283.01M | -81.10M | 120.81M | 71.40M | 5.78M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 447.22M | 302.92M | 183.62M | 181.56M | 237.64M | Total Assets |
| 690.57M | 532.88M | 403.29M | 339.78M | 364.39M | Total Debt |
| 10.97M | 14.13M | 15.36M | 0.00 | 0.00 | Net Debt |
| -180.69M | -175.39M | -72.29M | -145.97M | -128.71M | Total Liabilities |
| 354.55M | 498.67M | 329.43M | 413.13M | 300.58M | Stockholders Equity |
| 336.02M | 34.21M | 73.86M | -73.35M | 63.80M |
| Cash Flow | Free Cash Flow | |||
| 118.27M | 94.14M | 11.49M | 27.94M | 60.33M | Operating Cash Flow |
| 126.84M | 102.06M | 20.58M | 36.05M | 66.51M | Investing Cash Flow |
| -149.47M | -22.54M | -91.23M | 45.23M | -6.45M | Financing Cash Flow |
| 25.99M | 21.77M | 13.97M | -68.40M | -8.59M |
Cellebrite DI Technical Analysis
Positive
20.14
Price Trends
18.85
Positive
20.60
Negative
18.79
Positive
Market Momentum
0.22
Negative
53.73
Neutral
72.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLBT, the sentiment is Positive. The current price of 20.14 is above the 20-day moving average (MA) of 19.16, above the 50-day MA of 18.85, and above the 200-day MA of 18.79, indicating a bullish trend. The MACD of 0.22 indicates Negative momentum. The RSI at 53.73 is Neutral, neither overbought nor oversold. The STOCH value of 72.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLBT.
Cellebrite DI Peers Comparison
Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $4.65B | 27.50 | 41.09% | ― | 10.40% | 14.78% | |
64 Neutral | $6.22B | ― | -17.68% | ― | 32.25% | 20.56% | |
63 Neutral | $4.82B | ― | -152.88% | ― | 23.41% | -222.82% | |
61 Neutral | $1.53B | 60.03 | 164.75% | ― | 8.53% | ― | |
60 Neutral | $3.70B | ― | -12.09% | ― | 11.79% | 35.35% | |
60 Neutral | $10.93B | 10.46 | -6.70% | 2.99% | 7.54% | -12.22% | |
56 Neutral | $4.81B | ― | -20.26% | ― | 10.38% | 6.88% |
* Technology Sector Average
Performance Comparison
CLBT
Cellebrite DI
19.71
8.44
74.89%
QLYS
Qualys
128.16
-37.82
-22.79%
VRNS
Varonis Systems
43.85
-1.15
-2.56%
RPD
Rapid7
24.09
-21.71
-47.40%
TENB
Tenable Holdings
31.26
-14.38
-31.51%
S
SentinelOne
18.91
-2.76
-12.74%
Cellebrite DI Earnings Call Summary
Earnings Call Date:Feb 13, 2025
(Q4-2024)
| % Change Since: -19.18%|
Next Earnings Date:May 14, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive performance with strong revenue, ARR growth, and cash flow metrics. While there are some challenges in the US federal sector and from market exits, the company anticipates these will be short-term issues. The achievements in revenue, cloud-based ARR, and FedRAMP status outweigh the lowlights.Q4-2024 Updates
Positive Updates
Exceeded Revenue and Adjusted EBITDA Targets
Cellebrite exceeded original revenue and adjusted EBITDA targets for 2024 and delivered at the higher end of ARR expectations. ARR grew 25% year-over-year to $396 million.
Strong Free Cash Flow
Achieved $122 million in free cash flow in 2024, indicating solid cash generation capabilities.
Rule of 50 Performance
Delivered a Rule of 50 performance with 25% ARR growth and 25% adjusted EBITDA margins.
Increased Cloud-Based ARR
ARR from cloud-based offerings nearly doubled to 17% of total ARR in 2024.
FedRAMP-Ready Status
Achieved FedRAMP-ready status at a high-level designation, opening future opportunities within the US federal sector.
Negative Updates
Federal Sector Headwinds
Faced modest headwinds from regime changes causing delays in US federal sector purchasing activity.
Impact from Exiting Certain Markets
Exiting certain countries is expected to modestly impact first-quarter results, though it contributed to improved gross retention.
Company Guidance
During the Cellebrite Fourth Quarter and Full Year 2024 Financial Results Conference Call, the company provided guidance for 2025, highlighting several key metrics. For the full year 2025, Cellebrite anticipates ARR growth between 21% and 25%, reaching $480 million to $495 million. Revenue is projected to increase by 20% to 22%, amounting to $480 million to $490 million. The company aims for adjusted EBITDA in the range of $113 million to $123 million, maintaining a margin of 24% to 25%. The guidance also emphasized the continuation of strong performance in subscription services, with expectations for further growth in their cloud-based solutions and increased penetration of their Guardian and Pathfinder products. The company plans to focus on sustaining top-line growth and enhancing profitability and free cash flow in the upcoming year.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.